Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
MIRM - Mirum Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$146.00
DETAILS
HIGH:
$185.00
LOW:
$118.00
MEDIAN:
$145.50
CONSENSUS:
$146.00
UPSIDE:
27.67%
Stock News
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026.
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Mirum Pharmaceuticals NASDAQ: MIRM executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026.
Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes.
Price Targets
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
$148.00
(was $121.91)
Lisa Walter
·
RBC Capital
Mirum Pharmaceuticals (MIRM) PT Raised to $146 at Citizens After ENDO Data Reveal
$146.00
(was $99.34)
CLSA
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
$150.00
(was $94.00)
Morgan Stanley
Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research
$145.00
(was $95.49)
Wolfe Research
Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital
$142.00
(was $104.83)
Joe Kim
·
RBC Capital
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
$165.00
(was $100.92)
Ryan Deschner
·
Raymond James
Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
$185.00
(was $110.08)
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
$138.00
(was $110.08)
Evercore ISI
Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
$136.00
(was $110.08)
Stifel Nicolaus
Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
$129.00
(was $110.08)
Robert W. Baird
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
$140.00
(was $105.79)
Morgan Stanley
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
$175.00
(was $107.92)
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
$112.00
(was $92.48)
Brian Skorney
·
Robert W. Baird
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
$150.00
(was $93.23)
H.C. Wainwright
Mirum Pharmaceuticals (MIRM) PT Raised to $126 at Evercore ISI
$126.00
(was $89.37)
Gavin Clark-Gartner
·
Evercore ISI
Mirum Pharmaceuticals (MIRM) PT Lowered to $118 at Leerink Partners
$118.00
(was $92.78)
Mani Foroohar
·
Leerink Partners
RBC Capital Defending Mirum Pharmaceuticals (MIRM) Amid 15% Drop: 'Buying Opportunity Ahead of Multiple De-risked Catalysts'
$128.00
(was $94.14)
Joe Kim
·
RBC Capital
Mirum Pharmaceuticals initiated with an Outperform at RBC Capital
$130.00
(was $102.83)
RBC Capital
Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright
$130.00
(was $94.29)
H.C. Wainwright
Mirum Pharmaceuticals price target raised to $101 from $94 at Evercore ISI
$101.00
(was $91.13)
Evercore ISI